NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00641-6174-01 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00641-6174-10 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
25021-0455-05 | 25021-0455 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | Feb. 29, 2020 | In Use | |
57884-2021-01 | 57884-2021 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 16, 2013 | In Use | ||
60429-0910-30 | 60429-0910 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Sept. 28, 2016 | Feb. 28, 2023 | No Longer Used | |
62935-0303-30 | 62935-0303 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb. 26, 2003 | In Use | |||
67457-0311-05 | 67457-0311 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Sept. 9, 2019 | In Use | ||
00591-5019-02 | 00591-5019 | Fulvestrant | Fulvestrant | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Aug. 22, 2019 | June 30, 2024 | In Use | |
23155-0170-31 | 23155-0170 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug. 31, 2023 | In Use | ||
23155-0687-41 | 23155-0687 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0688-41 | 23155-0688 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0689-41 | 23155-0689 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
00781-9055-12 | 00781-9055 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | July 1, 2023 | In Use | ||
43598-0233-11 | 43598-0233 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug. 21, 2023 | In Use | ||
51655-0227-26 | 51655-0227 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 15, 2023 | In Use | ||
51655-0227-52 | 51655-0227 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | June 28, 2023 | In Use | ||
51655-0860-52 | 51655-0860 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 9, 2023 | In Use | ||
51655-0860-26 | 51655-0860 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | May 4, 2023 | In Use | ||
55150-0394-02 | 55150-0394 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intravenous | June 30, 2023 | In Use | ||
68788-8481-01 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8481-03 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8481-06 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8481-09 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8484-01 | 68788-8484 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8484-03 | 68788-8484 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use |
Found 10,000 results in 7 milliseconds — Export these results